CY1118430T1 - Θεραπευτικοι παραγοντες για τη ρυθμιση του φωσφορου εντος του ορου - Google Patents

Θεραπευτικοι παραγοντες για τη ρυθμιση του φωσφορου εντος του ορου

Info

Publication number
CY1118430T1
CY1118430T1 CY20161101220T CY161101220T CY1118430T1 CY 1118430 T1 CY1118430 T1 CY 1118430T1 CY 20161101220 T CY20161101220 T CY 20161101220T CY 161101220 T CY161101220 T CY 161101220T CY 1118430 T1 CY1118430 T1 CY 1118430T1
Authority
CY
Cyprus
Prior art keywords
compound
treatment
subunits
administered
therapeutic factors
Prior art date
Application number
CY20161101220T
Other languages
Greek (el)
English (en)
Inventor
Felix Karim
Gregory Bell
Original Assignee
Kai Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kai Pharmaceuticals, Inc. filed Critical Kai Pharmaceuticals, Inc.
Publication of CY1118430T1 publication Critical patent/CY1118430T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY20161101220T 2011-06-08 2016-11-24 Θεραπευτικοι παραγοντες για τη ρυθμιση του φωσφορου εντος του ορου CY1118430T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161494874P 2011-06-08 2011-06-08
PCT/US2012/041759 WO2012170955A1 (en) 2011-06-08 2012-06-08 Therapeutic agents for regulating serum phosphorus

Publications (1)

Publication Number Publication Date
CY1118430T1 true CY1118430T1 (el) 2017-06-28

Family

ID=46321485

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101220T CY1118430T1 (el) 2011-06-08 2016-11-24 Θεραπευτικοι παραγοντες για τη ρυθμιση του φωσφορου εντος του ορου

Country Status (23)

Country Link
US (1) US8969299B2 (enExample)
EP (1) EP2717896B1 (enExample)
JP (1) JP5982473B2 (enExample)
KR (1) KR102057508B1 (enExample)
CN (1) CN103857405B (enExample)
AU (1) AU2012267470C1 (enExample)
BR (1) BR112013031539A2 (enExample)
CA (1) CA2837445C (enExample)
CY (1) CY1118430T1 (enExample)
DK (1) DK2717896T3 (enExample)
ES (1) ES2607986T3 (enExample)
HR (1) HRP20161566T1 (enExample)
HU (1) HUE032087T2 (enExample)
LT (1) LT2717896T (enExample)
MX (1) MX337613B (enExample)
PL (1) PL2717896T3 (enExample)
PT (1) PT2717896T (enExample)
RS (1) RS55503B1 (enExample)
RU (1) RU2612912C2 (enExample)
SG (1) SG195290A1 (enExample)
SI (1) SI2717896T1 (enExample)
SM (2) SMT201700081T1 (enExample)
WO (1) WO2012170955A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4154900B1 (en) 2009-07-29 2024-08-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
CN114376970A (zh) 2013-06-28 2022-04-22 美国安进公司 Etelcalcetide (AMG 416)的稳定的液体制剂
RU2686086C1 (ru) * 2018-05-17 2019-04-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом
CN118496313A (zh) * 2019-12-09 2024-08-16 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物及其应用
CN115087662B (zh) * 2020-09-10 2023-09-26 陕西麦科奥特科技有限公司 双特异性融合多肽化合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
WO1992008476A1 (en) 1990-11-07 1992-05-29 The Scripps Research Institute Peptides that inhibit platelet binding of adhesion molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1995006056A1 (en) 1993-08-20 1995-03-02 University Of Medicine & Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
CA2145214A1 (en) 1995-02-28 1996-08-29 Rick E. Preddie Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5895368A (en) * 1996-09-23 1999-04-20 Medisystems Technology Corporation Blood set priming method and apparatus
WO1998017299A1 (en) 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
JP2000336099A (ja) 1999-05-27 2000-12-05 Sekisui Chem Co Ltd ペプチド及びc型肝炎抗体検出用試薬
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
IL153378A0 (en) 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
US20080249016A1 (en) 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20020168354A1 (en) 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
WO2002057413A2 (en) 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
AU2002240312A1 (en) 2001-02-08 2002-08-19 Pankaj Paranjp Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US20030036627A1 (en) 2001-02-16 2003-02-20 Montelaro Ronald C. Virus derived antimicrobial peptides
BRPI0207502B1 (pt) 2001-02-23 2018-10-09 Polyphor Ltd compostos, enanciômeros, composição farmacêutica, uso de compostos, e, processo para a fabricação de compostos
JP2005287302A (ja) 2002-04-03 2005-10-20 Haruhiko Fujiwara ポリペプチドの架橋方法
WO2004039940A2 (en) 2002-05-14 2004-05-13 Bristol-Myers Squibb Company Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof
WO2004093821A2 (en) 2003-04-22 2004-11-04 Hawaii Biotech, Inc. Treatment of anthrax infection using inhibitors of lethal factor protease activity
EP1680446B1 (en) 2003-11-05 2007-10-31 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
EP1699813A2 (en) 2003-12-11 2006-09-13 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific antagonists of protein kinase c
WO2005072340A2 (en) 2004-01-27 2005-08-11 Compugen Ltd. Novel polynucleotides encoding polypeptides and methods using same
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
ITME20040015A1 (it) * 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
AU2006285127A1 (en) 2005-08-30 2007-03-08 Acologix, Inc. Regulation of mineral and skeletal metabolism
WO2007038172A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
US8987200B2 (en) 2006-11-16 2015-03-24 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
AU2008206077A1 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
NZ584048A (en) 2007-10-02 2012-08-31 Marina Biotech Inc Lipopeptides for delivery of nucleic acids
EP2229473A4 (en) 2007-12-07 2011-02-02 Steven A Goldstein IDENTIFICATION OF TOXIN LIGANDS
EP4154900B1 (en) 2009-07-29 2024-08-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels

Also Published As

Publication number Publication date
JP2014522414A (ja) 2014-09-04
AU2012267470B2 (en) 2017-06-15
DK2717896T3 (en) 2016-12-19
RU2013157928A (ru) 2015-07-20
WO2012170955A1 (en) 2012-12-13
SMT201700081T1 (it) 2017-03-08
SI2717896T1 (sl) 2017-04-26
CN103857405A (zh) 2014-06-11
EP2717896A1 (en) 2014-04-16
KR102057508B1 (ko) 2019-12-19
BR112013031539A2 (pt) 2019-07-30
US8969299B2 (en) 2015-03-03
AU2012267470C1 (en) 2017-09-21
SMT201700081B (it) 2017-03-08
CA2837445A1 (en) 2012-12-13
SG195290A1 (en) 2013-12-30
US20130150301A1 (en) 2013-06-13
RU2612912C2 (ru) 2017-03-13
MX2013014249A (es) 2014-01-24
ES2607986T3 (es) 2017-04-05
LT2717896T (lt) 2017-02-27
HUE032087T2 (en) 2017-08-28
EP2717896B1 (en) 2016-08-24
PT2717896T (pt) 2016-12-23
PL2717896T3 (pl) 2017-05-31
RS55503B1 (sr) 2017-05-31
CA2837445C (en) 2022-10-04
CN103857405B (zh) 2015-12-02
HRP20161566T1 (hr) 2017-02-24
MX337613B (es) 2016-03-10
JP5982473B2 (ja) 2016-08-31
KR20140035456A (ko) 2014-03-21

Similar Documents

Publication Publication Date Title
CY1123255T1 (el) Σχημα δοσολογιας για εναν αγωνιστη υποδοχεα s1p
CY1122687T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο
CY1123688T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20
CY1123571T1 (el) Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα
CY1122428T1 (el) Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19
CY1121041T1 (el) Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
EA201590693A1 (ru) Ингибиторы gdf-8
NZ601677A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin d1
CY1116321T1 (el) Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p
BR112015006176A8 (pt) método de tratamento de câncer em um indivíduo com necessidade de tratamento
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
EA202090338A1 (ru) Функционально-модифицированные олигонуклеотиды и их субъединицы
CY1117964T1 (el) Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης τεχνικος τομεας
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
CO2017012454A2 (es) Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia
EA201491007A1 (ru) Лекарственные составы
CY1122746T1 (el) Ιατρικες αγωγες με βαση την αναμορελινη
CY1123583T1 (el) Ανοσογονος συνθεση για χρηση στη θεραπεια
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
CY1122403T1 (el) Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης
SG195290A1 (en) Therapeutic agents for regulating serum phosphorus
EA201390417A1 (ru) Антидиабетические твердые фармацевтические композиции